GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society, Vol. 84, No. 7 ( 1999-07), p. 2398-2401
    Type of Medium: Online Resource
    ISSN: 0021-972X , 1945-7197
    RVK:
    Language: English
    Publisher: The Endocrine Society
    Publication Date: 1999
    detail.hit.zdb_id: 2026217-6
    detail.hit.zdb_id: 3029-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    The Endocrine Society ; 2001
    In:  The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 8 ( 2001-08-01), p. 3611-3617
    In: The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society, Vol. 86, No. 8 ( 2001-08-01), p. 3611-3617
    Abstract: There is little consensus regarding the most appropriate dose regimen for radioiodine (131I) in the treatment of hyperthyroidism. We audited 813 consecutive hyperthyroid patients treated with radioiodine to compare the efficacy of 2 fixed-dose regimens used within our center (185 megabequerels, 370 megabequerels) and to explore factors that may predict outcome. Patients were categorized into 3 diagnostic groups: Graves’ disease, toxic nodular goiter, and hyperthyroidism of indeterminate etiology. Cure after a single dose of 131I was investigated and defined as euthyroid off all treatment for 6 months or T4 replacement for biochemical hypothyroidism in all groups. As expected, patients given a single dose of 370 megabequerels had a higher cure rate than those given 185 megabequerels, (84.6% vs. 66.6%, P & lt; 0.0001) but an increase in hypothyroidism incidence at 1 yr (60.8% vs. 41.3%, P & lt; 0.0001). There was no difference in cure rate between the groups with Graves’ disease and those with toxic nodular goiter (69.5% vs. 71.4%; P, not significant), but Graves’ patients had a higher incidence of hypothyroidism (54.5% vs. 31.7%, P & lt; 0.0001). Males had a lower cure rate than females (67.6% vs. 76.7%, P = 0.02), whereas younger patients ( & lt;40 yr) had a lower cure rate than patients over 40 yr old (68.9% vs. 79.3%, P & lt; 0.001). Patients with more severe hyperthyroidism (P & lt; 0.0001) and with goiters of medium or large size (P & lt; 0.0001) were less likely to be cured after a single dose of 131I. The use of antithyroid drugs, during a period 2 wk before or after 131I, resulted in a significant reduction in cure rate in patients given 185 megabequerels 131I (P & lt; 0.01) but not 370 megabequerels. Logistic regression analysis showed dose, gender, goiters of medium or large size, and severity of hyperthyroidism to be significant independent prognostic factors for cure after a single dose of 131I. We have demonstrated that a single fixed dose of 370 megabequerels 131I is highly effective in curing toxic nodular hyperthyroidism as well as Graves’ hyperthyroidism. Because male patients and those with more severe hyperthyroidism and medium or large-sized goiters are less likely to respond to a single dose of radioiodine, we suggest that the value of higher fixed initial doses of radioiodine should be evaluated in these patient categories with lower cure rates.
    Type of Medium: Online Resource
    ISSN: 0021-972X , 1945-7197
    RVK:
    Language: English
    Publisher: The Endocrine Society
    Publication Date: 2001
    detail.hit.zdb_id: 2026217-6
    detail.hit.zdb_id: 3029-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    The Endocrine Society ; 2000
    In:  The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 3 ( 2000-03-01), p. 1038-1042
    In: The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society, Vol. 85, No. 3 ( 2000-03-01), p. 1038-1042
    Abstract: The response to treatment in Graves’ hyperthyroidism is unpredictable, and factors postulated to predict outcome have not generally proved clinically useful or been widely adopted in clinical practice. We audited outcome in 536 patients with Graves’ hyperthyroidism presenting consecutively to determine whether simple clinical features predict disease presentation and response to treatment. At presentation males had slightly more severe biochemical hyperthyroidism [free T4: males, 64.3 ± 3.0 pmol/L (mean ± se); females, 61.3 ± 1.7 (P = 0.45); free T3: males, 24.3 ± 1.5 pmol/L; females, 21.0 ± 0.6, (P = 0.04)]. Patients less than 40 yr at diagnosis had more severe hyperthyroidism than patients more than 40 yr old [free T4: & lt;40 yr, 64.3 ± 2.0; & gt;40 yr, 56.7 ± 2.3 (P = 0.02); free T3: & lt;40 yr, 22.8 ± 0.8; & gt;40 yr, 19.0 ± 0.9 (P = 0.003)]. Males had a lower remission r ate than females after a course of antithyroid medication [19.6% vs. 40%; odds ratio, 0.37; 95% confidence interval (CI), 0.17–0.79; P & lt; 0.01]. Similarly, patients aged less than 40 yr had a lower remission rate than older patients (32.6% vs. 47.8%; odds ratio, 0.53; 95% CI, 0.32–0.87; P = 0.01). One dose of radioiodine cured hyperthyroidism in fewer males than females (47% vs. 74%; P & lt; 0.0001). Logistic regression analysis demonstrated male sex (odds ratio, 2.80; 95% CI, 1.31–5.98; P = 0.008), serum free T4 concentration at diagnosis (odds ratio, 1.02; 95% CI, 1.0–1.04; P = 0.01), and dose of radioiodine administered (odds ratio, 0.99; 95% CI, 0.99–1.00; P = 0.001) were contributing factors associated with failure to respond to a single dose of radioiodine. As males and younger patients are more likely to fail to respond to medical treatment, and male patients are likewise less likely to respond to a single dose of radioiodine, we suggest that those groups with low remission rates should be offered definitive treatment with radioiodine or surgery soon after presentation and that the value of higher initial doses of radioiodine in males be evaluated
    Type of Medium: Online Resource
    ISSN: 0021-972X , 1945-7197
    RVK:
    Language: English
    Publisher: The Endocrine Society
    Publication Date: 2000
    detail.hit.zdb_id: 2026217-6
    detail.hit.zdb_id: 3029-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Clinical Endocrinology, Wiley, Vol. 41, No. 4 ( 1994-10), p. 425-432
    Abstract: OBJECTIVE The results of studies examining the influence of T4 therapy upon bone mineral density (BMD) are conflicting. This conflict may, in part, reflect Inclusion of patients with varying thyroid disorders. We have therefore examined the influence of preceding thyroid history and T4 therapy on BMD. DESIGN Case‐control studies of patients on long‐term T4 therapy who have or have not previously received radio‐iodine treatment for thyrotoxicosis, as well as previously thyrotoxic patients who have not required T4 replacement. PATIENTS Twenty‐seven premenopausal and 60 post‐menopausal females with a past history of thyrotoxicosis and subsequent T4 treated hypothyroidism (group l), 39 post‐menopausal females with a past history of radio‐iodine treated thyrotoxicosis not receiving T4 (group 2) and 22 post‐menopausal females with primary hypothyroidism on T4 (group 3). Female controls individually matched to patients by age and menopausal status. MEASUREMENTS BMD measured by dual‐energy X‐ray absorptiometry. Serum biochemistry and tests of thyroid function. RESULTS No significant differences were found in femoral or lumbar spine BMD measurements between premenopausal patients and controls in group 1 or between group 2 patients and controls. Measurements of BMD at all sites were lower in post‐menopausal patients in groups 1 and 2 than in controls; when allowance was made for differences In BMD due to body mass index by analysis of variance, significant reductions in femoral trochanter BMD (3·9%, P 〈 0·05) and lumbar spine (5·6–8·5%, P 〈 0·01) BMD results were found in post‐menopausal females In group 1 and reductions in femoral trochanter (3·9%, P 〈 0·01), Ward's triangle (5·6%, P 〈 0·05) and lumbar spine (8·5%, P 〈 0·01) BMD results in group 2. Separate analysis of BMD results of those with normal or reduced serum TSH did not affect outcome. BMD measurements were not significantly correlated with duration of T4 therapy, T4 dose, or serum free T4 or TSH in any patient group. CONCLUSIONS Thyroxine therapy alone does not represent a significant risk factor for loss of bone mineral density but there is a risk of bone loss in post‐menopausal (but not premenopausal) females with a previous history of thyrotoxicosis treated with radioiodine.
    Type of Medium: Online Resource
    ISSN: 0300-0664 , 1365-2265
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 1994
    detail.hit.zdb_id: 121745-8
    detail.hit.zdb_id: 2004597-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society, Vol. 83, No. 10 ( 1998-10), p. 3394-3397
    Type of Medium: Online Resource
    ISSN: 0021-972X , 1945-7197
    RVK:
    Language: English
    Publisher: The Endocrine Society
    Publication Date: 1998
    detail.hit.zdb_id: 2026217-6
    detail.hit.zdb_id: 3029-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...